Loading…
Loading…
NNOX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NNOX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NNOX and 80,000+ other tickers.
See exactly how NNOX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NNOX and 80,000+ other tickers.
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based…
PETACH TIKVA, Israel, Aug. 25, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2026, before market open on Monday, September, 9, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Guy Nathanzon, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Initial three-year term includes minimum annual license commitments PETACH TIKVA, ISRAEL, August 18 2026 -- Nanox Imaging Ltd. (“ Nanox”, or the “Company” NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced its subsidiary, Nanox AI Ltd.
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 26-cv-07062, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nano-X securities between March 31, 2025 and April 17, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
New York, New York--(Newsfile Corp. - August 11, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
LOS ANGELES, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nano-X Imaging Ltd., (“Nano-X” or the "Company") (NASDAQ: NNOX) investors of a class action on behalf of investors that bought securities between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”).